Blood Res.  2021 Mar;56(1):56-58. 10.5045/br.2021.2020210.

Coagulopathy profiles and their correlation with molecular viral burden in patients with COVID-19

• Park HS
• Shin KS
• Son BR

• KMID: 2514068
• DOI: http://doi.org/10.5045/br.2021.2020210

Abstract

No abstract available

Figure

• 

  Fig. 1 Changes in coagulopathy-related parameters and inflammation marker over time after confirmation of SARS-CoV-2 infection. Shown are absolute lymphocyte count (A), platelet count (B), CRP (C), PT (D), aPTT (E), fibrinogen (F). The median is shown as a line across the box. The box stretches from the lower 25th percentile to the upper 75th percentile. The minimum value is above the lower inner fence, and the maximum value is the inner fence. The symbol ‘◦’ means that a value is outside the inner fence. The symbol ‘*’ means that a value is outside the outer fence.Abbreviations: aPTT, activated partial thromboplastin time; CRP, C-reactive protein; PT, prothrombin time.

Reference

1. Goeijenbier M, van Wissen M, van de Weg C, et al. 2012; Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 84:1680–96. DOI: 10.1002/jmv.23354. PMID: 22930518. PMCID: PMC7166625.

2. Assinger A. 2014; Platelets and infection - an emerging role of platelets in viral infection. Front immunol. 5:649. DOI: 10.3389/fimmu.2014.00649. PMID: 25566260. PMCID: PMC4270245.

3. Connors JM, Levy JH. 2020; COVID-19 and its implications for thrombosis and anticoagulation. Blood. 135:2033–40. DOI: 10.1182/blood.2020006000. PMID: 32339221. PMCID: PMC7273827.

4. Li Q, Cao Y, Chen L, et al. 2020; Hematological features of persons with COVID-19. Leukemia. 34:2163–72. DOI: 10.1038/s41375-020-0910-1. PMID: 32528042. PMCID: PMC7289481.

5. Lu R, Zhao X, Li J, et al. 2020; Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395:565–74. DOI: 10.1016/S0140-6736(20)30251-8. PMID: 32007145. PMCID: PMC7159086.

6. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. 2020; Hematological findings and complications of COVID-19. Am J Hematol. 95:834–47. DOI: 10.1002/ajh.25829. PMID: 32282949. PMCID: PMC7262337.

7. Yang M, Ng MH, Li CK. 2005; Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology. 10:101–5. DOI: 10.1080/10245330400026170. PMID: 16019455.

8. Kim ES, Choe PG, Park WB, et al. 2016; Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci. 31:1717–25. DOI: 10.3346/jkms.2016.31.11.1717. PMID: 27709848. PMCID: PMC5056202.

9. Joob B, Wiwanitkit V. 2015; Magnitude to thrombocytopenia among the patients with novel Middle East respiratory syndrome. Platelets. 26:612. DOI: 10.3109/09537104.2014.934796. PMID: 24984004.

10. Carmo A, Pereira-Vaz J, Mota V, et al. 2020; Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19. J Med Virol. 92:2227–31. DOI: 10.1002/jmv.26103. PMID: 32484958. PMCID: PMC7301002.

11. Perlman S, Dandekar AA. 2005; Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 5:917–27. DOI: 10.1038/nri1732. PMID: 16322745. PMCID: PMC7097326.

12. Liu WD, Chang SY, Wang JT, et al. 2020; Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect. 81:318–56. DOI: 10.1016/j.jinf.2020.03.063. PMID: 32283147. PMCID: PMC7151379.

13. Shim E, Tariq A, Choi W, Lee Y, Chowell G. 2020; Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 93:339–44. DOI: 10.1016/j.ijid.2020.03.031. PMID: 32198088. PMCID: PMC7118661.